Overview of the global bacterial vaginosis drugs market
Technavio’s market study identifies the rising awareness about women's health as one of the primary growth factors for the bacterial vaginosis drugs market. Owing to recent advancements in healthcare and the initiatives taken by the government and non-government organizations to increase the awareness about the health of women, the demand for pharmaceuticals related to disorders in women will witness a significant increase in the coming years.
Several governments and non-government organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have already come up with several programs to support the women health and wellness across the globe. Suh initiatives will propel the need for women health-related pharmaceuticals such as bacterial vaginosis drugs and BV infection medication, fueling market growth. Our market research analysts estimate that this market will generate a revenue of almost USD 1 billion by 2021.
Bacterial vaginosis drugs market trends
The effect of antibiotics is restricted by antibiotic resistance, that renders the antibiotics incapable of killing the bacteria. Antibiotic resistance is caused by the over-prescription of antibiotics, poor infection control in clinics and hospitals, poor sanitation, and lack of hygiene and results in longer treatment regime, longer hospitalizations, and increased side effects. The rising prevalence of infectious diseases and the lack of antibiotic regulations in developing and under-developed countries demand awareness campaigns regarding the excess usage of antibiotics. According to this industry research report, the growing awareness about the controlled use of antibiotics will be one of the key trends that will gain traction in the bacterial vaginosis drugs market during the coming years.
Bacterial vaginosis drugs market worth: Competitive landscape and key vendors
The bacterial vaginosis drugs market is highly fragmented due to the presence of several international and regional players who offer generic drugs. Small companies having significant positions in the generic drugs market are competing strongly with the large established vendors. The growth of the vendors in the BV infection treatment market is influenced by factors such as the lack of effective treatment and high unmet need specifically in the BV infection treatment. Vendors in the BV infection treatment market compete intensely on aggressive pricing and are focusing on geographic expansions.
The leading vendors in the market are
- Bayer
- Pfizer
- Sanofi
- Starpharma Holdings
Bacterial vaginosis drugs market segmentation by route of administration
The oral route of administration (ROA) is highly preferred as it has a systematic effect and reaches different parts of the body through the bloodstream, provides the convenience of intake, and low cost to the patients. Physicians suggest pregnant women suffering from BV to intake medicines only through the oral ROA.
Bacterial vaginosis drugs market forecast based on geographical segmentation
The high investment in the healthcare sector in the US and the high prevalence of BV infection in women residing is contributing to the growth of the BV infection treatment market in the Americas. Additionally, initiatives taken by the government and private organizations to increase the awareness about women’s health will also fuel the growth prospects of the market in this region.
Get more value with Technavio’s subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Start your 14-day FREE trial
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global bacterial vaginosis drugs market?
- What are the key market trends impacting the growth of the global bacterial vaginosis drugs market?
- What are the challenges to market growth?
- Who are the key vendors in the global bacterial vaginosis drugs market?
- What are the market opportunities and threats faced by the vendors in the global bacterial vaginosis drugs market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global bacterial vaginosis drugs market?
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Pipeline analysis
PART 07: Market segmentation by ROA
PART 08: Geographical segmentation
- BV drugs market in Americas
- BV drugs market in EMEA
- BV drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
- Market drivers
- Market challenges
PART 11: Market trends
- Growing awareness about controlled use of antibiotics
- Rising popularity of topical drugs and other treatment options such as probiotic drugs
PART 12: Vendor landscape
PART 13: Key vendor analysis
- Bayer
- Pfizer
- Sanofi
- Starpharma Holdings
- Other prominent vendors
PART 14: Appendix